AC Immune S.A.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ACIU research report →
Range $7 – $10
Price Chart
About the company
AC Immune S. A. is a biotech firm operating at the clinical stage, dedicated to pioneering, formulating, and advancing therapeutic agents and diagnostic tools.
- CEO
- Martin Zügel
- IPO
- 2016
- Employees
- 106
- HQ
- Lausanne, VD, CH
Get TickerSpark's AI analysis on ACIU
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $256.47M
- P/E
- -4.87
- Fwd P/E
- 12.47
- PEG
- 0.24
- P/S
- 12.20
- P/B
- 5.89
- EV/EBITDA
- -4.52
- Div Yield
- 0.00%
- Gross Margin
- 100.00%
- Op Margin
- -252.25%
- Net Margin
- -246.49%
- ROE
- -99.17%
- ROIC
- -86.61%
Latest fiscal year · YoY change
- Revenue
- $3.57M-86.9%
- Gross Profit
- $3.57M+110.1%
- Op Income
- $-68,863,000
- Net Income
- $-70,447,000-38.4%
- EPS
- $-0.70-37.3%
- OCF Growth
- -200.5%
- FCF Growth
- -202.7%
- 52W High
- $4.00
- 52W Low
- $2.10
- 50D MA
- $2.61
- 200D MA
- $2.81
- Beta
- 1.55
- RSI (14)
- 43
- Avg Volume
- 201.25K
No earnings-call transcripts are available for ACIU yet.
- Free Float
- 61.5%
- Shares Outstanding
- 101.77M
- Float Shares
- 62.57M
of shares held by institutions
51 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Bvf Inc/Il | 19.82M | 0 |
| Wells Fargo & Company/Mn | 1.00M | ▼ 243 |
| Renaissance Technologies LLC | 840.13K | ▲ 215.76K |
| Millennium Management LLC | 773.59K | ▼ 19.06K |
| Blackrock, Inc. | 519.27K | ▼ 5.00K |
| Dimensional Fund Advisors LP | 340.08K | ▼ 50.08K |
| Arrowstreet Capital, Limited Partnership | 232.95K | ▼ 172.71K |
| Citadel Advisors LLC | 207.61K | ▼ 59.63K |
| Morgan Stanley | 131.81K | ▲ 42.56K |
| Two Sigma Investments, LP | 102.83K | ▲ 63.73K |
| Deeter Investments Llp | 100.00K | 0 |
| Qube Research & Technologies Ltd | 92.35K | ▲ 92.35K |
Held by 21 ETFs
Biggest fund positions in ACIU by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 11, 26 | Twyman Roy Ervin | other | 16,568 |
| Jun 11, 26 | Twyman Roy Ervin | other | 38,889 |
| Jun 11, 26 | AGUIAR-LUCANDER RENEE | other | 16,568 |
| Jun 11, 26 | AGUIAR-LUCANDER RENEE | other | 38,889 |
| Jun 11, 26 | Zuegel Martin | other | 77,778 |
| Jun 11, 26 | Zuegel Martin | other | 33,136 |
| Jun 11, 26 | Buetler Monika | other | 17,751 |
| Jun 11, 26 | Buetler Monika | other | 41,667 |
| Jun 11, 26 | June Carl Howard | other | 16,568 |
| Jun 11, 26 | June Carl Howard | other | 38,889 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ACIU coverage
Recent articles, reports, and earnings notes.
No research on ACIU yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ACIU report →Best Momentum Stock to Buy for September 30th
zacks.com · Sep 30
AC Immune Parkinson's Vaccine Study Meets Safety, Immunogenicity Goals
marketbeat.com · Sep 26
AC Immune: Buy Continued ACI-7104 Progress, PD, And Pipeline Expansions
seekingalpha.com · Sep 24
AC Immune Reports Positive Safety & Immunogenicity at week-100 in Part 1 of VacSYn Phase 2 Trial of ACI-7104
globenewswire.com · Sep 23
AC Immune Announces Positive Preliminary Phase 1 Data for NLRP3 Inhibitor ACI-19764
globenewswire.com · Aug 20
AC Immune (ACIU) Beats Q2 Earnings and Revenue Estimates
zacks.com · Aug 5
AC Immune First Half 2026 Financial and Corporate Update
globenewswire.com · Aug 5
AC Immune to Showcase Neurodegenerative Disease Pipeline with Three Presentations at AAIC® 2026
globenewswire.com · Jul 7
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.